726 related articles for article (PubMed ID: 33728149)
1. A Case of Metastatic Pancreatic Adenocarcinoma in Complete Remission Using Chemotherapy and Immunotherapy.
Atiq S; Atiq OO; Atiq ZO; Samad S; Atiq O
Cureus; 2021 Feb; 13(2):e13133. PubMed ID: 33728149
[TBL] [Abstract][Full Text] [Related]
2. Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma.
Patil NR; Khan GN
Am J Case Rep; 2020 Jul; 21():e923803. PubMed ID: 32658872
[TBL] [Abstract][Full Text] [Related]
3. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Maintained Complete Response and Long-Term Survival in Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer with Erlotinib.
Alkassis S; Alshare B; Ahmed S
Cureus; 2021 Jan; 13(1):e12451. PubMed ID: 33552769
[TBL] [Abstract][Full Text] [Related]
6. Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.
Pang X; Qian J; Jin H; Zhang L; Lin L; Wang Y; Lei Y; Zhou Z; Li M; Zhang H
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636238
[TBL] [Abstract][Full Text] [Related]
7. Seventy-two Cycles of FOLFIRINOX: Long Term Treatment in a Patient with Metastatic Adenocarcinoma of the Pancreatic Tail.
Tiller M; Gundling F; Schepp W; Fuchs M
JOP; 2015 Mar; 16(2):205-8. PubMed ID: 25791559
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment with afatinib for pancreatic metastasis of lung adenocarcinoma: a case report.
Furuya T; Shimada J; Okada S; Tsunezuka H; Kato D; Inoue M
J Thorac Dis; 2017 Oct; 9(10):E890-E893. PubMed ID: 29268429
[TBL] [Abstract][Full Text] [Related]
9. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
[TBL] [Abstract][Full Text] [Related]
10. The seemingly innocuous presentation of metastatic pancreatic tail cancer: a case report.
Rahman M; Washington L
J Med Case Rep; 2019 Jun; 13(1):178. PubMed ID: 31182138
[TBL] [Abstract][Full Text] [Related]
11. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
Kourie H; Auclin E; Cunha AS; Gaujoux S; Bruzzi M; Sauvanet A; Lourenco N; Trouilloud I; Louafi S; El-Hajjar A; Vaillant JC; Smith D; Touchefeu Y; Bachet JB; Pietrasz D; Taieb J
Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):663-668. PubMed ID: 31029644
[TBL] [Abstract][Full Text] [Related]
12. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
[TBL] [Abstract][Full Text] [Related]
13. Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma.
Cao C; Parikh P; Moezardalan K; Anantharaman A; Azarm A; Lai J
Anticancer Res; 2020 Jul; 40(7):4029-4032. PubMed ID: 32620648
[TBL] [Abstract][Full Text] [Related]
14. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
15. A first described chest wall metastasis from colon cancer demonstrated with (18)F-FDG PET/CT.
Jiang L; Gao Y; Sheng S; Xu M; Lu L; Lu H
Hell J Nucl Med; 2011; 14(3):316-7. PubMed ID: 22087459
[TBL] [Abstract][Full Text] [Related]
16. Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.
Kim YI; Kim SK; Paeng JC; Lee HY
Eur J Radiol; 2014 Jan; 83(1):231-5. PubMed ID: 24290142
[TBL] [Abstract][Full Text] [Related]
17. Searching for novel multimodal treatments in oligometastatic pancreatic cancer.
Filippini DM; Grassi E; Palloni A; Carloni R; Casadei R; Ricci C; Serra C; Ercolani G; Brandi G; Di Marco M
BMC Cancer; 2020 Mar; 20(1):271. PubMed ID: 32228504
[TBL] [Abstract][Full Text] [Related]
18. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
[TBL] [Abstract][Full Text] [Related]
20. Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers.
Kuwatani M; Kawakami H; Eto K; Haba S; Shiga T; Tamaki N; Asaka M
Intern Med; 2009; 48(11):867-75. PubMed ID: 19483354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
